Roivant and Priovant Host Investor Conference to Discuss Brepocitinib's Dermatomyositis Potential

Roivant Sciences and Priovant Therapeutics will host an investor video conference on June 17, 2025, to discuss brepocitinib, a potential treatment for dermatomyositis (DM). The conference will focus on the unmet medical need in DM and the clinical trials evaluating brepocitinib's effectiveness. Investors can register online or access the archived webcast on Roivant's website.

Roivant Sciences and Priovant Therapeutics will host an investor video conference on June 17, 2025, to discuss brepocitinib, a potential treatment for dermatomyositis (DM). The conference will focus on the unmet medical need in DM and the clinical trials evaluating brepocitinib's effectiveness. Investors can register online or access the archived webcast on Roivant's website [1].

Brepocitinib is a dual selective inhibitor of TYK2 and JAK1, developed by Priovant Therapeutics. It is designed to suppress key cytokines linked to autoimmunity, including type I IFN, type II IFN, IL-6, IL-12, and IL-23, with a single, targeted therapy. The drug has been dosed in over 1,400 subjects and has generated positive data in seven Phase 2 studies. Brepocitinib is currently being evaluated in Phase 3 trials for dermatomyositis, non-infectious uveitis, and Phase 2 trials for cutaneous sarcoidosis [2].

Roivant Sciences, a biopharmaceutical company, is involved in the development and commercialization of brepocitinib. Roivant's pipeline includes brepocitinib, IMVT-1402, and batoclimab, among others. The company aims to improve patients' lives by accelerating the development and commercialization of medicines that matter [1].

The video conference will provide an opportunity for investors to learn more about brepocitinib's potential role in improving the lives of patients with DM. The conference will likely cover the clinical and therapeutic potential of brepocitinib, as well as the results of ongoing clinical trials. Investors are encouraged to register online or access the archived webcast on Roivant's website [1].

References:
[1] https://investor.roivant.com/news-releases/news-release-details/roivant-and-priovant-host-investor-video-conference-100-pm-et
[2] https://www.globenewswire.com/news-release/2025/06/09/3096179/0/en/Roivant-and-Priovant-to-Host-Investor-Video-Conference-at-1-00-PM-ET-on-Tuesday-June-17-on-Brepocitinib-and-the-Unmet-Medical-Need-in-Dermatomyositis.html